BiomX Inc. Q3 2025 Earnings Recap

PHGE Q3 2025 November 12, 2025

BiomX reported significant advancements in its clinical programs despite regulatory challenges, maintaining confidence in its innovative phage therapy pipeline.

Earnings Per Share Beat

$-5.51 vs $-6.08 est.

+9.4% surprise

Market Reaction

1-Day -6.99%

5-Day -28.81%

30-Day -67.69%

Key Takeaways

Initiated Phase IIb trial for BX004 with first patient dosing, though faced a temporary clinical hold from the FDA related to the nebulizer delivery device.
Received positive FDA feedback on BX011’s development for diabetic foot infections, outlining a clear pathway towards a Biologics License Application (BLA).
European trials for BX004 continue without interruption, with planned data reporting set for Q1 2026.
BX011 targets a critical unmet need in diabetic foot infections, promising substantial commercial potential in a market with no new drugs approved in over 20 years.
Company remains optimistic about upcoming discussions with the FDA and the Department of Defense Health Agency as part of its strategic partnerships.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit PHGE on AllInvestView.

Previous Q2 2025